Cargando…
Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus
Appropriate adjuvant selection may be essential to optimize the potency and to tailor the immune response of subunit vaccines. To induce protective responses against respiratory syncytial virus (RSV)—a highly prevalent childhood pathogen without a licensed vaccine—we previously engineered a pre-fusi...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658087/ https://www.ncbi.nlm.nih.gov/pubmed/29073183 http://dx.doi.org/10.1371/journal.pone.0186854 |
_version_ | 1783273930455252992 |
---|---|
author | Sastry, Mallika Zhang, Baoshan Chen, Man Joyce, M. Gordon Kong, Wing-Pui Chuang, Gwo-Yu Ko, Kiyoon Kumar, Azad Silacci, Chiara Thom, Michelle Salazar, Andres M. Corti, Davide Lanzavecchia, Antonio Taylor, Geraldine Mascola, John R. Graham, Barney S. Kwong, Peter D. |
author_facet | Sastry, Mallika Zhang, Baoshan Chen, Man Joyce, M. Gordon Kong, Wing-Pui Chuang, Gwo-Yu Ko, Kiyoon Kumar, Azad Silacci, Chiara Thom, Michelle Salazar, Andres M. Corti, Davide Lanzavecchia, Antonio Taylor, Geraldine Mascola, John R. Graham, Barney S. Kwong, Peter D. |
author_sort | Sastry, Mallika |
collection | PubMed |
description | Appropriate adjuvant selection may be essential to optimize the potency and to tailor the immune response of subunit vaccines. To induce protective responses against respiratory syncytial virus (RSV)—a highly prevalent childhood pathogen without a licensed vaccine—we previously engineered a pre-fusion-stabilized trimeric RSV F (pre-F) “DS-Cav1” immunogen, which induced high titer RSV-neutralizing antibodies, in mice and non-human primates, when formulated with adjuvants Poly (I:C) and Poly (IC:LC), respectively. To assess the impact of different adjuvants, here we formulated RSV F DS-Cav1 with multiple adjuvants and assessed immune responses. Very high RSV-neutralizing antibody responses (19,006 EC(50)) were observed in naïve mice immunized with 2 doses of DS-Cav1 adjuvanted with Sigma adjuvant system (SAS), an oil-in-water adjuvant, plus Carbopol; high responses (3658–7108) were observed with DS-Cav1 adjuvanted with Alum, SAS alone, Adjuplex, Poly (I:C) and Poly (IC:LC); and moderate responses (1251–2129) were observed with DS-Cav1 adjuvanted with the TLR4 agonist MPLA, Alum plus MPLA or AddaVax. In contrast, DS-Cav1 without adjuvant induced low-level responses (6). A balanced IgG1 and IgG2a (Th2/Th1) immune response was elicited in most of the high to very high response groups (all but Alum and Adjuplex). We also tested the immune response induced by DS-Cav1 in elderly mice with pre-existing DS-Cav1 immunity; we observed that DS-Cav1 adjuvanted with SAS plus Carbopol boosted the response 2-3-fold, whereas DS-Cav1 adjuvanted with alum boosted the response 5-fold. Finally, we tested whether a mixture of ISA 71 VG and Carbopol would enhanced the antibody response in DS-Cav1 immunized calves. While pre-F-stabilized bovine RSV F induced very high titers in mice when adjuvanted with SAS plus Carbopol, the addition of Carbopol to ISA 71 VG did not enhance immune responses in calves. The vaccine response to pre-F-stabilized RSV F is augmented by adjuvant, but the degree of adjuvant-induced enhancement appears to be both context-dependent and species-specific. |
format | Online Article Text |
id | pubmed-5658087 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-56580872017-11-09 Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus Sastry, Mallika Zhang, Baoshan Chen, Man Joyce, M. Gordon Kong, Wing-Pui Chuang, Gwo-Yu Ko, Kiyoon Kumar, Azad Silacci, Chiara Thom, Michelle Salazar, Andres M. Corti, Davide Lanzavecchia, Antonio Taylor, Geraldine Mascola, John R. Graham, Barney S. Kwong, Peter D. PLoS One Research Article Appropriate adjuvant selection may be essential to optimize the potency and to tailor the immune response of subunit vaccines. To induce protective responses against respiratory syncytial virus (RSV)—a highly prevalent childhood pathogen without a licensed vaccine—we previously engineered a pre-fusion-stabilized trimeric RSV F (pre-F) “DS-Cav1” immunogen, which induced high titer RSV-neutralizing antibodies, in mice and non-human primates, when formulated with adjuvants Poly (I:C) and Poly (IC:LC), respectively. To assess the impact of different adjuvants, here we formulated RSV F DS-Cav1 with multiple adjuvants and assessed immune responses. Very high RSV-neutralizing antibody responses (19,006 EC(50)) were observed in naïve mice immunized with 2 doses of DS-Cav1 adjuvanted with Sigma adjuvant system (SAS), an oil-in-water adjuvant, plus Carbopol; high responses (3658–7108) were observed with DS-Cav1 adjuvanted with Alum, SAS alone, Adjuplex, Poly (I:C) and Poly (IC:LC); and moderate responses (1251–2129) were observed with DS-Cav1 adjuvanted with the TLR4 agonist MPLA, Alum plus MPLA or AddaVax. In contrast, DS-Cav1 without adjuvant induced low-level responses (6). A balanced IgG1 and IgG2a (Th2/Th1) immune response was elicited in most of the high to very high response groups (all but Alum and Adjuplex). We also tested the immune response induced by DS-Cav1 in elderly mice with pre-existing DS-Cav1 immunity; we observed that DS-Cav1 adjuvanted with SAS plus Carbopol boosted the response 2-3-fold, whereas DS-Cav1 adjuvanted with alum boosted the response 5-fold. Finally, we tested whether a mixture of ISA 71 VG and Carbopol would enhanced the antibody response in DS-Cav1 immunized calves. While pre-F-stabilized bovine RSV F induced very high titers in mice when adjuvanted with SAS plus Carbopol, the addition of Carbopol to ISA 71 VG did not enhance immune responses in calves. The vaccine response to pre-F-stabilized RSV F is augmented by adjuvant, but the degree of adjuvant-induced enhancement appears to be both context-dependent and species-specific. Public Library of Science 2017-10-26 /pmc/articles/PMC5658087/ /pubmed/29073183 http://dx.doi.org/10.1371/journal.pone.0186854 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Sastry, Mallika Zhang, Baoshan Chen, Man Joyce, M. Gordon Kong, Wing-Pui Chuang, Gwo-Yu Ko, Kiyoon Kumar, Azad Silacci, Chiara Thom, Michelle Salazar, Andres M. Corti, Davide Lanzavecchia, Antonio Taylor, Geraldine Mascola, John R. Graham, Barney S. Kwong, Peter D. Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus |
title | Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus |
title_full | Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus |
title_fullStr | Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus |
title_full_unstemmed | Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus |
title_short | Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus |
title_sort | adjuvants and the vaccine response to the ds-cav1-stabilized fusion glycoprotein of respiratory syncytial virus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658087/ https://www.ncbi.nlm.nih.gov/pubmed/29073183 http://dx.doi.org/10.1371/journal.pone.0186854 |
work_keys_str_mv | AT sastrymallika adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT zhangbaoshan adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT chenman adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT joycemgordon adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT kongwingpui adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT chuanggwoyu adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT kokiyoon adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT kumarazad adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT silaccichiara adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT thommichelle adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT salazarandresm adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT cortidavide adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT lanzavecchiaantonio adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT taylorgeraldine adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT mascolajohnr adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT grahambarneys adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus AT kwongpeterd adjuvantsandthevaccineresponsetothedscav1stabilizedfusionglycoproteinofrespiratorysyncytialvirus |